PL2906592T3 - Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji - Google Patents

Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji

Info

Publication number
PL2906592T3
PL2906592T3 PL13779699T PL13779699T PL2906592T3 PL 2906592 T3 PL2906592 T3 PL 2906592T3 PL 13779699 T PL13779699 T PL 13779699T PL 13779699 T PL13779699 T PL 13779699T PL 2906592 T3 PL2906592 T3 PL 2906592T3
Authority
PL
Poland
Prior art keywords
improved expression
bacterial extracts
proteolytic inactivation
select proteins
proteins
Prior art date
Application number
PL13779699T
Other languages
English (en)
Inventor
Christopher D. Thanos
Christopher J. Murray
Junhao Yang
Heather STEPHENSON
Original Assignee
Sutro Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma, Inc. filed Critical Sutro Biopharma, Inc.
Publication of PL2906592T3 publication Critical patent/PL2906592T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PL13779699T 2012-10-12 2013-10-08 Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji PL2906592T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713245P 2012-10-12 2012-10-12
PCT/US2013/063804 WO2014058830A1 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of select proteins in bacterial extracts for improved expression
EP13779699.1A EP2906592B1 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Publications (1)

Publication Number Publication Date
PL2906592T3 true PL2906592T3 (pl) 2019-07-31

Family

ID=49447839

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13779699T PL2906592T3 (pl) 2012-10-12 2013-10-08 Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji

Country Status (14)

Country Link
US (3) US9650621B2 (pl)
EP (1) EP2906592B1 (pl)
JP (3) JP6421122B2 (pl)
KR (1) KR102018863B1 (pl)
CN (1) CN104837863B (pl)
AU (1) AU2013329464C1 (pl)
CA (1) CA2887355C (pl)
DK (1) DK2906592T3 (pl)
ES (1) ES2694683T3 (pl)
HU (1) HUE041721T2 (pl)
IL (1) IL238095B (pl)
PL (1) PL2906592T3 (pl)
SG (1) SG11201502875VA (pl)
WO (1) WO2014058830A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2906592T3 (pl) * 2012-10-12 2019-07-31 Sutro Biopharma, Inc. Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji
SG11201508642WA (en) * 2013-04-19 2015-11-27 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
US10316322B2 (en) * 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
CN116144626A (zh) * 2016-01-13 2023-05-23 新英格兰生物实验室公司 T7 rna聚合酶的热稳定变体
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN106801047A (zh) * 2016-12-30 2017-06-06 武汉金开瑞生物工程有限公司 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法
JP7325341B2 (ja) 2017-07-11 2023-08-14 シンソークス,インク. 非天然ヌクレオチドの組み込み及びその方法
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
SG11202003147XA (en) 2017-10-12 2020-05-28 Vaxcyte Inc Periodontitis vaccine and related compositions and method of use
CN112004547A (zh) 2018-02-26 2020-11-27 新索思股份有限公司 Il-15缀合物及其用途
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN108949796A (zh) * 2018-07-27 2018-12-07 张家港市华天药业有限公司 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
CN109055291A (zh) * 2018-07-31 2018-12-21 张家港市华天药业有限公司 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
SG11202102930YA (en) 2018-11-08 2021-04-29 Synthorx Inc Interleukin 10 conjugates and uses thereof
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
KR20210146392A (ko) 2019-04-02 2021-12-03 박사이트, 인코포레이티드 침습 플라스미드 항원 b의 최적화된 무세포 합성 및 관련 조성물 및 사용 방법
CN114555128A (zh) 2019-08-15 2022-05-27 新索思股份有限公司 采用il-2缀合物的免疫肿瘤学组合疗法
US12234271B2 (en) 2019-09-10 2025-02-25 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
WO2021091986A1 (en) 2019-11-04 2021-05-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
US12351850B2 (en) * 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
IL299074A (en) 2020-06-25 2023-02-01 Synthorx Inc Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates
US20220089690A1 (en) * 2020-09-14 2022-03-24 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
JP2023546010A (ja) 2020-10-09 2023-11-01 シンソークス, インコーポレイテッド Il-2コンジュゲートを用いた免疫腫瘍療法
IL301611A (en) 2020-10-09 2023-05-01 Synthorx Inc Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
WO2022174102A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
CN113322267B (zh) * 2021-03-15 2024-01-05 天津大学 系统在提高非天然氨基酸的插入效率中的应用
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
EP4452327A1 (en) 2021-12-20 2024-10-30 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
CN121263208A (zh) 2023-03-20 2026-01-02 新索思股份有限公司 使用il-2 peg缀合物的癌症疗法
WO2025015041A1 (en) * 2023-07-12 2025-01-16 University Of Washington Rna-only, positive control target for clinical diagnostic testing
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052193A1 (fr) * 1999-03-04 2000-09-08 Suntory Limited Procede de controle de clivage par la protease de l'ompt
DE60226411D1 (de) 2001-01-25 2008-06-19 Anthony C Forster Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
JP5259046B2 (ja) 2002-08-19 2013-08-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 改良されたインビトロ・タンパク質合成の方法
DE10336705A1 (de) * 2003-08-06 2005-03-10 Rina Netzwerk Rna Technologien Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese
US9657323B2 (en) 2003-09-30 2017-05-23 Daiichi Sankyo Company, Limited Polypeptide cleavage method using OmpT protease variant
WO2006082059A1 (en) * 2005-02-02 2006-08-10 Universität Bayreuth Esterases for monitoring protein biosynthesis in vitro
BRPI0617191A2 (pt) * 2005-10-12 2011-07-19 Scripps Research Inst modificação pós-traducional de polipeptìdeos expressos em fagos
WO2007109035A2 (en) * 2006-03-16 2007-09-27 The Scripps Research Institute Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine
JP5798489B2 (ja) 2009-01-12 2015-10-21 ストロ バイオファーマ, インコーポレイテッド インビトロタンパク質合成システムを用いて非天然アミノ酸をタンパク質に選択的に導入するためのモノチャージシステム
PL2906592T3 (pl) 2012-10-12 2019-07-31 Sutro Biopharma, Inc. Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji

Also Published As

Publication number Publication date
JP2021003134A (ja) 2021-01-14
KR102018863B1 (ko) 2019-09-05
US20170283469A1 (en) 2017-10-05
US20150259664A1 (en) 2015-09-17
IL238095A0 (en) 2015-05-31
JP2015531407A (ja) 2015-11-02
ES2694683T3 (es) 2018-12-26
US20200062807A1 (en) 2020-02-27
AU2013329464A1 (en) 2015-05-14
CN104837863A (zh) 2015-08-12
AU2013329464B2 (en) 2017-07-27
WO2014058830A1 (en) 2014-04-17
SG11201502875VA (en) 2015-06-29
KR20150064209A (ko) 2015-06-10
CA2887355C (en) 2023-03-07
EP2906592B1 (en) 2018-10-03
DK2906592T3 (en) 2018-12-10
US11261219B2 (en) 2022-03-01
JP6421122B2 (ja) 2018-11-07
CN104837863B (zh) 2018-06-19
US10450353B2 (en) 2019-10-22
EP2906592A1 (en) 2015-08-19
CA2887355A1 (en) 2014-04-17
AU2013329464C1 (en) 2018-02-15
HUE041721T2 (hu) 2019-05-28
JP2018029621A (ja) 2018-03-01
US9650621B2 (en) 2017-05-16
IL238095B (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL238095B (en) Proteolytic inactivation of selected proteins in bacterial extraction to improve expression
IL286784A (en) Compositions of protein and antibody
IL234621A0 (en) Loaded dietary proteins and methods
ZA201408662B (en) Microbial fermentation methods and compositions
PL2855662T3 (pl) Rekombinowane mikroorganizmy i ich zastosowania
SG11201501254RA (en) Recombinant microorganisms and uses therefor
ZA201400562B (en) Axmi205 variant proteins and methods for their use
IL230918A0 (en) Modified proteins and peptides
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
EP2670847A1 (en) Methods and materials for enhancing functional protein expression in bacteria
PL2678432T3 (pl) Rekombinowane mikroorganizmy i ich zastosowania
ZA201508529B (en) Bacterial fermentation methods and compositions
PT2665818T (pt) Expressão de proteínas em plantas
IL233481A0 (en) Peptides and methods of using them
PT2804875T (pt) Ferramentas e métodos para expressão de proteínas de membrana
EP2718432A4 (en) NUCLEASE FUSION PROTEIN AND USES THEREOF
AP2014007708A0 (en) Method for highly expressing recombinant protein of engineering bacteria and use thereof
IL231715A (en) Liquid protein supplement that has been sterilized
PT2851083T (pt) Composição proteica resistente à esterilização por radiação
GB201213672D0 (en) Protein
GB201103169D0 (en) Protein expression
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides
GB201215901D0 (en) Protein modification
FI20115950L (fi) Probioottisia bakteereita sisältävä elintarvike